(S)-N-(piperidin-3-ylmethyl)-7-p-tolylpyrido[4,3-d]pyrimidin-5-amine

ID: ALA4570737

PubChem CID: 155561444

Max Phase: Preclinical

Molecular Formula: C20H23N5

Molecular Weight: 333.44

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1ccc(-c2cc3ncncc3c(NC[C@H]3CCCNC3)n2)cc1

Standard InChI:  InChI=1S/C20H23N5/c1-14-4-6-16(7-5-14)18-9-19-17(12-22-13-24-19)20(25-18)23-11-15-3-2-8-21-10-15/h4-7,9,12-13,15,21H,2-3,8,10-11H2,1H3,(H,23,25)/t15-/m0/s1

Standard InChI Key:  CCYQRHUBQPXAQK-HNNXBMFYSA-N

Molfile:  

 
     RDKit          2D

 25 28  0  0  0  0  0  0  0  0999 V2000
   12.0460   -2.5176    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.0448   -3.3371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.7529   -3.7461    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.7511   -2.1087    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.4597   -2.5140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.4605   -3.3330    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1690   -3.7401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8773   -3.3292    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8725   -2.5071    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.1634   -2.1037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5830   -3.7310    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5848   -4.5493    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2933   -4.9551    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.0004   -4.5437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9946   -3.7223    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2855   -3.3202    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1591   -1.2866    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.8646   -0.8742    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5745   -1.2791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5742   -2.0931    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2800   -2.4979    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9879   -2.0890    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9855   -1.2709    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.2752   -0.8616    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.7102   -4.9486    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  6  2  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10  5  1  0
 11 12  2  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 11  1  0
  8 11  1  0
 10 17  1  0
 17 18  1  0
 19 18  1  6
 19 20  1  0
 19 24  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 14 25  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4570737

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 333.44

Molecular Weight (Monoisotopic): 333.1953

AlogP: 3.41

#Rotatable Bonds: 4

Polar Surface Area: 62.73

Molecular Species: BASE

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 10.17

CX LogP: 2.97

CX LogD: 0.32

Aromatic Rings: 3

Heavy Atoms: 25

QED Weighted: 0.77

Np Likeness Score: -0.99

References

1. Garton NS, Barker MD, Davis RP, Douault C, Hooper-Greenhill E, Jones E, Lewis HD, Liddle J, Lugo D, McCleary S, Preston AGS, Ramirez-Molina C, Neu M, Shipley TJ, Somers DO, Watson RJ, Wilson DM..  (2016)  Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors.,  26  (19): [PMID:27578246] [10.1016/j.bmcl.2016.08.070]

Source

Source(1):

• Scientific Literature